Sugi Predict

Sugi Predict / Compounds / SCHEMBL4501585

SCHEMBL4501585

SCHEMBL4501585

O=C(/C=C/c1ccc(O)cc1)OCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B10 O60218 6/20 1.00
▸ AKR1B1 P15121 6/20 1.00
▸ CA12 O43570 6/20 1.00
▸ CA7 P43166 6/20 1.00
▸ CA9 Q16790 6/20 1.00
▸ CA14 Q9ULX7 6/20 1.00
▸ CA4 P22748 4/20 1.00
▸ CA6 P23280 4/20 1.00
▸ CA5A P35218 4/20 1.00
▸ CA5B Q9Y2D0 4/20 1.00
▸ LMNA P02545 1/20 0.84
▸ MAOB P27338 1/20 0.76
▸ TTR P02766 1/20 0.74
▸ CA1 P00915 4/20 0.64
▸ CA2 P00918 2/20 0.64
▸ MET P08581 2/20 0.63
▸ HCAR2 Q8TDS4 1/20 0.63
▸ ABCG2 Q9UNQ0 1/20 0.58
▸ MMP1 P03956 1/20 0.57
▸ MMP2 P08253 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501587 1.00 AKR1B10 (1.00) AKR1B10AKR1B1CA12CA7CA9
SCHEMBL15419990 1.00 AKR1B10 (1.00) AKR1B10AKR1B1CA12CA7CA9
SCHEMBL13552179 0.95 LMNA (0.93) AKR1B10AKR1B1CA12CA7CA9
SCHEMBL22510990 0.94 AKR1B10 (0.88) AKR1B10AKR1B1CA12CA7CA9
Benzyl Cinnamate SCHEMBL43212 0.92 LMNA (1.00) AKR1B10AKR1B1CA12CA7CA9
Benzyl Cinnamate SCHEMBL1871854 0.92 LMNA (1.00) AKR1B10AKR1B1CA12CA7CA9
Benzyl Cinnamate SCHEMBL43213 0.92 LMNA (1.00) AKR1B10AKR1B1CA12CA7CA9
Benzyl Cinnamate SCHEMBL901152 0.92 LMNA (1.00) AKR1B10AKR1B1CA12CA7CA9
SCHEMBL22071063 0.90 LMNA (0.84) AKR1B10AKR1B1CA12CA7CA9
SCHEMBL29641956 0.89 LMNA (0.82) AKR1B10AKR1B1CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110658294-A Method for detecting aspen type propolis 浙江大学 2020-01-07 — — CN claimed
CN-106596757-B A method of the propolis place of production is identified based on p- tonka-bean acid benzyl ester content 中国农业科学院蜜蜂研究所 2019-08-20 — — CN claimed
US-20260132163-A1 BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) 2026-05-14 — — US disclosed
US-12545699-B2 Bivalent LECA inhibitors targeting biofilm formation of Pseudomonas aeruginosa Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2026-02-10 — — US disclosed
EP-4346810-A1 COMPOSITIONS FOR REGULATING HOMEOSTASIS OF CORTISOL AND IMPROVING SLEEP QUALITY AND METHODS OF USE AND PRODUCTION THEREOF Unigen, Inc. (US) 2024-04-10 — — EP disclosed
CN-117794534-A Compositions for modulating cortisol homeostasis and improving sleep quality and methods of use and preparation thereof 尤尼根公司 2024-03-29 — — CN disclosed
CN-117476126-B Propolis flavone extraction method for targeted preparation of uric acid-reducing activity and application 中国农业科学院蜜蜂研究所 2024-03-19 — — CN disclosed
CN-117476126-A Propolis flavone extraction method for targeted preparation of uric acid-reducing activity and application 中国农业科学院蜜蜂研究所 2024-01-30 — — CN disclosed
CN-112569219-B Medicine for treating artery related diseases and application thereof 中国科学院上海药物研究所 2023-05-02 — — CN disclosed
US-20220402960-A1 BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-12-22 — — US disclosed
WO-2022256624-A1 COMPOSITIONS FOR REGULATING HOMEOSTASIS OF CORTISOL AND IMPROVING SLEEP QUALITY AND METHODS OF USE AND PRODUCTION THEREOF UNIGEN, INC. (US) 2022-12-08 — — WO disclosed
US-7468391-B2 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2008-12-23 — — US disclosed
US-7468391-B2 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2008-12-23 — — US disclosed
US-7468391-B2 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2008-12-23 — — US disclosed
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2008-01-03 — — US disclosed
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2008-01-03 — — US disclosed
US-7226951-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2007-06-05 — — US disclosed
US-7226951-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2007-06-05 — — US disclosed
US-20050187298-A1 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2005-08-25 — — US disclosed
US-20050176689-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. 2005-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132163-A1 BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA ALG1, FUT6, CSGALNACT1 AKR1B10 2093/4885AKR1B1 1230/4885CA12 355/4885
US-20050176689-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 AKR1B10 141/4885AKR1B1 99/4885CA12 3105/4885
US-20050187298-A1 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B CYP26B1, CYP2A6, CYP21A2 AKR1B10 55/4885AKR1B1 24/4885CA12 2544/4885
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 AKR1B10 141/4885AKR1B1 99/4885CA12 3105/4885
US-20220402960-A1 BIVALENT LECA INHIBITORS TARGETING BIOFILM FORMATION OF PSEUDOMONAS AERUGINOSA PHOSPHO1, PEBP1, LPCAT1 AKR1B10 4230/4885AKR1B1 4347/4885CA12 1990/4885
US-12545699-B2 Bivalent LECA inhibitors targeting biofilm formation of Pseudomonas aeruginosa FUT6, ALG1, FUT5 AKR1B10 4339/4885AKR1B1 3858/4885CA12 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.